Based on the Personalis Inc stock forecast from 5 analysts, the average analyst target price for Personalis Inc is USD 8.13 over the next 12 months. Personalis Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Personalis Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Personalis Inc’s stock price was USD 3.29. Personalis Inc’s stock price has changed by -2.66% over the past week, -9.37% over the past month and +165.32% over the last year.
No recent analyst target price found for Personalis Inc
No recent average analyst rating found for Personalis Inc
Company Overview Personalis Inc
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California. Read Less
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrenc...Read More
Frequently Asked Questions About Personalis Inc (PSNL) Stock
Based on ratings from 5 analysts Personalis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on PSNL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for PSNL is USD 8.13 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
PSNL stock's Price/Earning ratio is 53.95.
Our analysis grades PSNL stock's Price / Earning ratio at F. This means that PSNL stock's Price/Earning ratio is above 70% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this PSNL may be a overvalued for its sector.
The last closing price of PSNL's stock was USD 3.29.
The most recent market capitalization for PSNL is USD 0.29B.
Based on targets from 5 analysts, the average taret price for PSNL is projected at USD 8.13 over the next 12 months.
This means that PSNL's stock price may go up by +146.96% over the next 12 months.
We can't find any ETFs which contains Personalis Inc's stock.
As per our most recent records Personalis Inc has 228 Employees.
Personalis Inc's registered address is 6600 Dumbarton Circle, Fremont, CA, United States, 94555.
You can get more information about it from Personalis Inc's website at https://www.personalis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Personalis Inc (PSNL) Stock
Based on ratings from 5 analysts Personalis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on PSNL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for PSNL is USD 8.13 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
PSNL stock's Price/Earning ratio is 53.95.
Our analysis grades PSNL stock's Price / Earning ratio at F. This means that PSNL stock's Price/Earning ratio is above 70% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this PSNL may be a overvalued for its sector.
The last closing price of PSNL's stock was USD 3.29.
The most recent market capitalization for PSNL is USD 0.29B.
Based on targets from 5 analysts, the average taret price for PSNL is projected at USD 8.13 over the next 12 months.
This means that PSNL's stock price may go up by +146.96% over the next 12 months.
We can't find any ETFs which contains Personalis Inc's stock.
As per our most recent records Personalis Inc has 228 Employees.
Personalis Inc's registered address is 6600 Dumbarton Circle, Fremont, CA, United States, 94555.
You can get more information about it from Personalis Inc's website at https://www.personalis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PSNL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
